BeOne Medicines Ltd
ONC
212 hedge funds and large institutions have $10.9B invested in BeOne Medicines Ltd in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 63 increasing their positions, 78 reducing their positions, and 44 closing their positions.
51% more capital invested
Capital invested by funds: $7.22B → $10.9B (+$3.66B)
37% more call options, than puts
Call options by funds: $36.6M | Put options by funds: $26.7M
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
0.31% less ownership
Funds ownership: 3.97% → 3.66% (-0.31%)
5% less funds holding
Funds holding: 223 → 212 (-11)
16% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 44
19% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 78
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$57.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$36.5M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$34.1M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$28.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$382M |
| 2 |
State Street
Boston,
Massachusetts
|
-$106M |
| 3 |
Goldman Sachs
New York
|
-$39.7M |
| 4 |
Legal & General Group
London,
United Kingdom
|
-$36.8M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$32.6M |
ONC Hedge Fund Activity: Q4 2022 in Review
212 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2022, worth a combined $10.9B — up 51% from $7.22B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ONC and 37 opened new positions — a net loss of 7 holders — while 78 trimmed existing stakes and 63 added.
The largest buyer was Primecap Management, adding an estimated $57.4M. The largest seller was BlackRock, cutting an estimated $382M.
- 212 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2022, down from 223 in Q3 2022.
- Funds reported $10.9B of BeOne Medicines Ltd stock for Q4 2022, up 51% quarter-over-quarter.
- 37 funds opened new BeOne Medicines Ltd positions in Q4 2022 and 44 closed out, a net change of -7 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2022 was Primecap Management, an estimated $57.4M added.
- The largest BeOne Medicines Ltd seller in Q4 2022 was BlackRock, an estimated $382M sold.
Based on aggregated 13F filings for Q4 2022.